BioSuite AI PortfolioVirtualBio LabVirtualBio Lab™
VirtualBio Lab™: Explore a virtual experiment. See how hypothetical PK/PD assumptions change simulated responses. Simulation demo.
VirtualBio Lab™See how hypothetical PK/PD assumptions change simulated responses.Explore a virtual experiment. · Simulation demo
PREM KUMARSCIENCE · LEADERSHIP · AI
PRECLINICAL RESEARCH · EDUCATIONAL DEMO

VirtualBio Lab ™

Explore simulated concentration–response variability across a virtual population.
VIRTUALBIO LAB™ / MODELLING

PK/PD modelling workspace

Explore how a hypothetical IV bolus, clearance, distribution volume and EC50 affect concentration and model response. Inputs for CL, V and EC50 are arithmetic population means.

Research demonstration only. This uses a hypothetical one-compartment PK model and Emax response model. No drug-specific parameters, clinical outcomes, human safety predictions or validated virtual patients are represented. Do not use for dosing, treatment or regulatory decisions.

Simulation overview

Median peak concentration—mg/L (hypothetical)
Median response at 1 h—% of model maximum
Median AUC₀–₂₄—mg·h/L

Virtual population concentration over time

Median with 5th–95th percentile envelope · 0–24 hours

Model response over time

Median with 5th–95th percentile envelope · arbitrary biological response

Evidence & reproducibility passport

ItemRecorded information
ModelOne-compartment IV bolus + Emax (illustrative)
Parameter sourcesHypothetical user-defined values; no empirical calibration
Virtual population—
Random seed—
UncertaintyBetween-person parameter variability; structural/model uncertainty not quantified
Validation statusNot validated; not for clinical use

VirtualBio Lab™ — Educational simulation evidence report

Inspect numerical results (49 time points)
Concentration in mg/L; model response in %. P05–P95 is simulated population variability.
HourC P05C medianC P95Response P05Response medianResponse P95

Scientific limitations & evidence status

Educational prototype. Not validated for clinical or regulatory use. All inputs are hypothetical. Synthetic parameter sets are not validated virtual patients, and model responses are not efficacy, toxicity or human safety predictions.

  • Single IV bolus only: no oral absorption, repeat dosing, compartments, metabolites or nonlinear elimination.
  • Independent lognormal clearance, volume and EC50; no physiological covariates, correlations, disease mechanisms or drug interactions.
  • Fixed Emax of 100% with a Hill coefficient of 1. Response is an arbitrary model output, not a measured endpoint.
  • The 5th–95th percentile envelope shows simulated parameter variability. It is not a confidence interval and does not include structural uncertainty or measurement error.
  • No empirical calibration, external validation, clinical evidence synthesis, or regulatory qualification has been performed. The evidence report records model provenance and reproducibility, not evidence of therapeutic benefit.

Do not use this demo for dosing, treatment, human safety predictions or regulatory decisions.